Larvol Delta - OP1250003-Phase-1b-Study-of-OP1250-Palazestrant-in-Combination-With-Ribociclib-Alpelisib-Everolimus-or-Atirmociclib-in-ER-HER2-Breast-Cancer

palazestrant (OP-1250) - Olema Pharma

everolimus - Generic mfg.

Kisqali (ribociclib) - Novartis

Piqray (alpelisib) - Novartis

atirmociclib (PF-07220060) - Pfizer

http://clinicaltrials.gov/ct2/show/NCT05508906

Sep 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next